Andere Sprachen Vir Biotechnology, Inc.

Aktien

A2PS0P

US92764N1028

VIR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
8,23 ^USD	+7,86 %		+3,52 %	-18,19 %

26.04.	Cytokinetics ernennt Sung Lee zum CFO	MT
18.04.	Vir Biotechnology, Inc. kündigt den Rücktritt von Sung Lee als Executive Vice President mit Wirkung zum 3. Mai 2024 an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cytokinetics Appoints Sung Lee as CFO	26.04.
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	18.04.
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	18.04.
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors	18.04.
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024	11.04.
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25.03.
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule	05.03.
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	05.03.
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	05.03.
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences	26.02.
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences	23.02.
Vir Biotechnology's Q4 Loss Widens, Revenue Declines	23.02.
Vir Biotechnology, GSK Terminate Collaboration on Flu	22.02.
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M	22.02.
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA	22.02.
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	22.02.
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22.02.
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer	20.02.
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer	20.02.
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vir Biotechnology, Inc.

Aktien

A2PS0P

US92764N1028

VIR

Andere Sprachen

Filter